Olaparib Monotherapy for Advanced Prostate Cancer With Mutations: TAPUR Update
Posted: Friday, August 7, 2020
According to findings presented during the ASCO20 Virtual Scientific Program (Abstract 5567), monotherapy with olaparib resulted in antitumor activity for heavily pretreated patients with prostate cancer with germline or somatic BRACA1/2-inactivating mutations. The phase II TAPUR study findings were part of the extended results of recent trials evaluating treatment with olaparib, noted Evan P. Pisick, MD, of Cancer Treatment Centers of America, Zion, Illinois, and colleagues.
In this basket study, the authors enrolled 29 patients with advanced prostate cancer and BRCA1/2-inactivating tumors who had no remaining standard treatment options. Patients received 300 mg of olaparib (24 patients) or 400 mg of olaparib (5 patients). After enrollment, four patients were deemed ineligible because of bone-alone disease and removed from analysis.
The authors reported nine patients had an objective response and eight patients had stable disease at 16 weeks, for disease control and overall response rates of 68% and 36%, respectively. Of the patients, six had at least one grade 3 adverse event or serious adverse event related to olaparib, including anemia, aspiration, dehydration, diabetic ketoacidosis, fatigue, and neutropenia.
Disclosure: For a full disclosure of the study authors, visit coi.asco.org.